Futura Medical (LSE:FUM) announced encouraging results from a four-week home user study evaluating its approved erectile dysfunction gel Eroxon alongside a new prototype formulation, Eroxon Intense. The trial involved 223 men in the UK, most of whom had mild to moderate erectile dysfunction, and showed that both products delivered meaningful improvements in erectile function compared with baseline. Participants also reported high satisfaction with erection hardness and duration, particularly when the gel was applied by a partner.
The study also demonstrated that Eroxon Intense produced a statistically stronger sensorial response during the first two minutes after application compared with the existing formulation. Both treatments were reported to be well tolerated by users and their partners. Futura said it plans to focus marketing on men under the age of 60 with mild to moderate erectile dysfunction, while highlighting partner involvement as part of foreplay.
The company has already submitted a Special 510(k) application to the U.S. Food and Drug Administration for Eroxon Intense and has gathered supporting data for regulatory filings across Europe. Decisions from regulators are anticipated during the first half of 2026.
Futura’s outlook is tempered by a sharply reduced FY2025 outlook outlined during its earnings call and a relatively short cash runway, alongside weak technical trend indicators. These factors are partly balanced by the company’s return to profitability in FY2024 and its debt-free balance sheet, although negative free cash flow continues to weigh on overall financial quality.
More about Futura Medical
Futura Medical is a UK-listed consumer healthcare company focused on the research, development and global commercialisation of topical gel-based treatments for sexual health. Its flagship product, Eroxon, is the only over-the-counter topical gel for erectile dysfunction. The company’s pipeline also includes Eroxon Intense and WSD4000, a candidate targeting female sexual dysfunction.
Leave a Reply